Héctor Soto Parrà

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

Luis Paz‐Ares, David Vicente, Ali Tafreshi et al. · Journal of Thoracic Oncology · 2020 · 633 citations · Full text

Protocol-specified Final Analysis, Medicine, Pembrolizumab Plus Chemotherapy +9

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 568 citations · Full text

Medicine, Immunology, Pathology +5

Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma

Giovanni Luca Ceresoli, Paolo Andrea Zucali, Adolfo Favaretto et al. · Journal of Clinical Oncology · 2006 · 293 citations

Gemcitabine in the Treatment of Refractory Hodgkin’s Disease: Results of a Multicenter Phase II Study

Armando Santoro, Henning Bredenfeld, Liliana Devizzi et al. · Journal of Clinical Oncology · 2000 · 228 citations